2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172277
    DSPE-PEG1000-R9 98%
    DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery.
    DSPE-PEG1000-R9
  • HY-172418
    Betovumeline 1314018-44-4 98%
    Betovumeline is the agonist for muscarinic receptor and can be used for researchs of neurological disorders.
    Betovumeline
  • HY-172419
    Blixeprodil 2881017-49-6 98%
    Blixeprodil (GM-1020) is the orally active antagonist for NMDA receptor with an affinity of Ki=3.25 µM in rat cortical tissue. Blixeprodil inhibits NR1/2A-NMDAR-mediated currents in HEK293 cell with IC50 of 1.192 µM. Blixeprodil exhibits antidepressant in rats models. Blixeprodil can cross blood-brain barrier.
    Blixeprodil
  • HY-172420
    Bretisilocin 2698331-35-8 98%
    Bretisilocin is the agonist for 5-HT2A receptor and exhibits antidepressant activity.
    Bretisilocin
  • HY-172421
    Cendifensine 1034048-49-1 98%
    Cendifensine is the inhibitor for monoamine reuptake that inhibits the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT).
    Cendifensine
  • HY-172425
    Deulumateperone 2102683-75-8 98%
    Deulumateperone is a deuterium labeled Lumateperone (HY-17637). Lumateperone is the orally active 5-HT2A receptor antagonist (Ki = 0.54 nM) and the modulator for dopamine receptor that exhibits antipsychotic and antineoplastic activities.
    Deulumateperone
  • HY-172427
    Elsovaptan 2296801-25-5 98%
    Elsovaptan is the antagonist for vasopressin receptor that can be used in researchs of Alzheimer disease.
    Elsovaptan
  • HY-172431
    Opakalim 2376397-93-0 98%
    Opakalim is the activator for potassium channel and exhibits antiepileptic activity.
    Opakalim
  • HY-172433
    Refisolone 202718-04-5 98%
    Refisolone is an antagonist of the GABAA receptor.
    Refisolone
  • HY-172436
    Rocavorexant 2115665-09-1 98%
    Rocavorexant is the antagonist for orexin-1 receptor with pIC50 of 9.1 for human OX1 (while pIC50 for human OX2 is 6.0).
    Rocavorexant
  • HY-172455
    TREK inhibitor-3 3023854-95-4 98%
    TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC50 of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke.
    TREK inhibitor-3
  • HY-172460
    AChE/BChE/MAO-B-IN-5 1432738-00-5 98%
    AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of cholinesterases (AChE and BChE) and monoamine oxidase MAO-B with blood–brain barrier permeability. It exhibits IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM against AChE, BChE, and MAO-B, respectively. AChE/BChE/MAO-B-IN-5 shows promise for research in the field of neurodegenerative diseases such as Alzheimer's disease.
    AChE/BChE/MAO-B-IN-5
  • HY-172461
    MAO-IN-6 98%
    MAO-IN-6 (Compound 3f) is a BBB permeable and reversible MAO-B inhibitor with an IC50 of 0.09 μM. MAO-IN-6 also exhibits certain inhibitory activities against AChE and BChE, with IC50 values of 4.48 μM and 17.03 μM, respectively. MAO-IN-6 has low cytotoxicity and can be used in the research of Alzheimer's disease.
    MAO-IN-6
  • HY-172529
    DPP9-IN-1 3020859-03-1
    DPP9-IN-1 (Compound 42) is a dipeptidyl peptidase 9 (DPP9) inhibitor with IC50 of 3 nM for DPP9 and 0.6 μM for DPP8. DPP9-IN-1 induces concentration-dependent LDH release in THP-1 cells.
    DPP9-IN-1
  • HY-172531
    Sulfonadyn-47 3064686-59-2 98%
    Sulfonadyn-47 is a GTP-competitive dynamin I (dynI) inhibitor that targets the active site in the GTPase domain of dynamin I, with IC50 values of 3.5 μM against dynI, 27.3 μM in clathrin-mediated endocytosis (CME) assays, and 12.3 μM in synaptic vesicle endocytosis (SVE) assays. Sulfonadyn-47 increases seizure threshold. Sulfonadyn-47 can be used the study for the seizure[1].
    Sulfonadyn-47
  • HY-172542
    TTBK1/2-IN-1 2342571-09-7 98%
    TTBK1/2-IN-1 (compound 3) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 816 nM and 384 nM, respectively.
    TTBK1/2-IN-1
  • HY-172543
    TTBK1/2-IN-2 2857982-35-3 98%
    TTBK1/2-IN-2 (compound 9) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 384 nM and 175 nM, respectively. TTBK1/2-IN-2 shows a significant ciliogenesis phenotype in human induced pluripotent stem cells (iPSCs).
    TTBK1/2-IN-2
  • HY-172544
    TTBK1/2-IN-3 2857982-34-2 98%
    TTBK1/2-IN-3 (compound 10) is a potent Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 579 nM and 258 nM, respectively. TTBK1/2-IN-3 reduces the expression of primary cilia on the surface of human induced pluripotent stem cells (iPSCs).
    TTBK1/2-IN-3
  • HY-172545
    AMG28 1202764-07-5 98%
    AMG28 is a Tau tubulin kinase 1 (TTBK1) and TTBK2 inhibitor with IC50s of 805 nM and 988 nM, respectively. AMG28 inhibits tau phosphorylation at Ser422 (IC50 of 1.85 μM).
    AMG28
  • HY-172550
    MS7710 98%
    MS7710 is a brain-penetrant inhibitor targeting the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. MS7710 reduces the Ih current and decreases the activity of ventral tegmental area (VTA) dopamine neurons by inhibiting HCN channels. MS7710 can effectively improve social interaction deficits and reward-related cognitive flexibility in the chronic social defeat stress (CSDS) mouse model. MS7710 is promising for research of depression.
    MS7710
Cat. No. Product Name / Synonyms Application Reactivity